Compugen (Israel) Top Management
| CGEN Stock | ILA 736.20 10.20 1.40% |
Compugen employs about 73 people. The company is managed by 26 executives with a total tenure of roughly 190 years, averaging almost 7.0 years of service per executive, having 2.81 employees per reported executive. Analysis of Compugen's management performance can provide insight into the company performance.
| Anat CohenDayag CEO President, Chief Executive Officer, Director |
| Paul Sekhri Chairman Chairman of the Board |
Compugen |
Compugen Management Team Effectiveness
The company has return on total asset (ROA) of (0.2301) % which means that it has lost $0.2301 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4394) %, meaning that it generated substantial loss on money invested by shareholders. Compugen's management efficiency ratios could be used to measure how well Compugen manages its routine affairs as well as how well it operates its assets and liabilities.Compugen Workforce Comparison
Compugen is number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 274. Compugen totals roughly 73.0 in number of employees claiming about 27% of stocks in Biotechnology industry.
Compugen Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Compugen Price Series Summation is a cross summation of Compugen price series and its benchmark/peer.
Compugen Notable Stakeholders
A Compugen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Compugen often face trade-offs trying to please all of them. Compugen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Compugen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Anat CohenDayag | President, Chief Executive Officer, Director | Profile | |
| Paul Sekhri | Chairman of the Board | Profile | |
| Martin Gerstel | Chairman of the Board | Profile | |
| Zurit Levine | Vice President - Research and Discovery | Profile | |
| Ari Krashin | Chief Financial Officer | Profile | |
| Joshua Shemer | Independent External Director | Profile | |
| Ruth Arnon | Independent Director | Profile | |
| Yair Aharonowitz | Independent External Director | Profile | |
| Michal Preminger | Director | Profile | |
| Dov Hershberg | Director | Profile | |
| Arie Ovadia | Independent External Director | Profile | |
| Eran Perry | Director | Profile | |
| Sanford Zweifach | Director | Profile | |
| Gilead Halevy | Director | Profile | |
| Kinneret Savitsky | Director | Profile | |
| JeanPierre Bizzari | Director | Profile | |
| John Hunter | VP of Antibody RandD and Site Head of Compugen USA Inc | Profile | |
| Rivka Schwartz | VP Discovery | Profile | |
| Eran Dor | Gen Sec | Profile | |
| Oliver Froescheis | Sr Devel | Profile | |
| Alberto Sessa | Chief Officer | Profile | |
| Henry MD | VP Officer | Profile | |
| Yvonne Naughton | Head Communications | Profile | |
| Henry Adewoye | Chief Medical Officer | Profile | |
| Dorit Amitay | VP HR | Profile |
About Compugen Management Performance
The success or failure of an entity such as Compugen often depends on how effective the management is. Compugen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Compugen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Compugen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel. COMPUGEN operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 68 people.
The data published in Compugen's official financial statements usually reflect Compugen's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Compugen. For example, before you start analyzing numbers published by Compugen accountants, it's critical to develop an understanding of what Compugen's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Compugen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Compugen's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Compugen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Compugen. Please utilize our Beneish M Score to check the likelihood of Compugen's management manipulating its earnings.
Compugen Workforce Analysis
Traditionally, organizations such as Compugen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Compugen within its industry.Compugen Manpower Efficiency
Return on Compugen Manpower
| Revenue Per Employee | 82.2K | |
| Revenue Per Executive | 230.8K | |
| Net Loss Per Employee | 468.5K | |
| Net Loss Per Executive | 1.3M | |
| Working Capital Per Employee | 1.2M | |
| Working Capital Per Executive | 3.2M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Compugen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Compugen Stock refer to our How to Trade Compugen Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Compugen Stock analysis
When running Compugen's price analysis, check to measure Compugen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compugen is operating at the current time. Most of Compugen's value examination focuses on studying past and present price action to predict the probability of Compugen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compugen's price. Additionally, you may evaluate how the addition of Compugen to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |